Potential Utility of Cerebrospinal Fluid Glycoprotein Nonmetastatic Melanoma Protein B as a Neuroinflammatory Diagnostic Biomarker in Mild Cognitive Impairment and Alzheimer’s Disease
Alzheimer’s disease (AD) is a very common neurodegenerative disorder characterized by the gradual loss of neurons and extracellular amyloid-peptide buildup. There is compelling evidence that the disease process depends on neuroinflammatory alterations, such as the activation of astrocytes and microg...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/14/4689 |
| _version_ | 1797588857439387648 |
|---|---|
| author | Julia Doroszkiewicz Agnieszka Kulczyńska-Przybik Maciej Dulewicz Renata Borawska Monika Zajkowska Agnieszka Słowik Barbara Mroczko |
| author_facet | Julia Doroszkiewicz Agnieszka Kulczyńska-Przybik Maciej Dulewicz Renata Borawska Monika Zajkowska Agnieszka Słowik Barbara Mroczko |
| author_sort | Julia Doroszkiewicz |
| collection | DOAJ |
| description | Alzheimer’s disease (AD) is a very common neurodegenerative disorder characterized by the gradual loss of neurons and extracellular amyloid-peptide buildup. There is compelling evidence that the disease process depends on neuroinflammatory alterations, such as the activation of astrocytes and microglia cells. A transmembrane glycoprotein known as glycoprotein nonmetastatic melanoma protein B (GPNMB) plays a neuroprotective role during the development of neurodegeneration. To the best of our knowledge, this is the first investigation discussing the potential clinical usefulness of this protein in the AD continuum, especially in the MCI (mild cognitive impairment) stage. A total of 71 patients with AD or MCI as well as controls were enrolled in this study. The concentrations of GPNMB, YKL-40, Aβ1-42 (amyloid beta 1-42), Tau, and pTau and the Aβ1-42/1-40 ratio in the CSF (cerebrospinal fluid) were tested using immunological methods. The concentrations of both GPNMB and YKL-40 in the cerebrospinal fluid were significantly higher in patients with AD and MCI compared to the controls. Moreover, both proteins were biochemically associated with classical biomarkers of AD and were especially associated with the Aβ1-42/1-40 ratio and Tau and pTau levels in the whole study group. Elevated concentrations of GPNMB were observed in the Aβ(+) group of AD patients compared to the Aβ(−) subjects. Additionally, the diagnostic performance (AUC value) of GPNMB was higher than that of amyloid β1-42 in MCI patients compared with controls. Our study indicates that GPNMB might be a promising neuroinflammatory biomarker for the early diagnosis and prognosis of the AD continuum, with potential utility as a therapeutic target. |
| first_indexed | 2024-03-11T00:57:58Z |
| format | Article |
| id | doaj.art-ae35e27150dd433f8b8adcc317767662 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-11T00:57:58Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-ae35e27150dd433f8b8adcc3177676622023-11-18T19:52:30ZengMDPI AGJournal of Clinical Medicine2077-03832023-07-011214468910.3390/jcm12144689Potential Utility of Cerebrospinal Fluid Glycoprotein Nonmetastatic Melanoma Protein B as a Neuroinflammatory Diagnostic Biomarker in Mild Cognitive Impairment and Alzheimer’s DiseaseJulia Doroszkiewicz0Agnieszka Kulczyńska-Przybik1Maciej Dulewicz2Renata Borawska3Monika Zajkowska4Agnieszka Słowik5Barbara Mroczko6Department of Neurodegeneration Diagnostics, Medical University of Bialystok, 15-269 Bialystok, PolandDepartment of Neurodegeneration Diagnostics, Medical University of Bialystok, 15-269 Bialystok, PolandDepartment of Neurodegeneration Diagnostics, Medical University of Bialystok, 15-269 Bialystok, PolandDepartment of Neurodegeneration Diagnostics, Medical University of Bialystok, 15-269 Bialystok, PolandDepartment of Neurodegeneration Diagnostics, Medical University of Bialystok, 15-269 Bialystok, PolandDepartment of Neurology, Jagiellonian University, 30-688 Cracow, PolandDepartment of Neurodegeneration Diagnostics, Medical University of Bialystok, 15-269 Bialystok, PolandAlzheimer’s disease (AD) is a very common neurodegenerative disorder characterized by the gradual loss of neurons and extracellular amyloid-peptide buildup. There is compelling evidence that the disease process depends on neuroinflammatory alterations, such as the activation of astrocytes and microglia cells. A transmembrane glycoprotein known as glycoprotein nonmetastatic melanoma protein B (GPNMB) plays a neuroprotective role during the development of neurodegeneration. To the best of our knowledge, this is the first investigation discussing the potential clinical usefulness of this protein in the AD continuum, especially in the MCI (mild cognitive impairment) stage. A total of 71 patients with AD or MCI as well as controls were enrolled in this study. The concentrations of GPNMB, YKL-40, Aβ1-42 (amyloid beta 1-42), Tau, and pTau and the Aβ1-42/1-40 ratio in the CSF (cerebrospinal fluid) were tested using immunological methods. The concentrations of both GPNMB and YKL-40 in the cerebrospinal fluid were significantly higher in patients with AD and MCI compared to the controls. Moreover, both proteins were biochemically associated with classical biomarkers of AD and were especially associated with the Aβ1-42/1-40 ratio and Tau and pTau levels in the whole study group. Elevated concentrations of GPNMB were observed in the Aβ(+) group of AD patients compared to the Aβ(−) subjects. Additionally, the diagnostic performance (AUC value) of GPNMB was higher than that of amyloid β1-42 in MCI patients compared with controls. Our study indicates that GPNMB might be a promising neuroinflammatory biomarker for the early diagnosis and prognosis of the AD continuum, with potential utility as a therapeutic target.https://www.mdpi.com/2077-0383/12/14/4689Alzheimer’s diseaseGPNMBYKL-40neuroinflammation |
| spellingShingle | Julia Doroszkiewicz Agnieszka Kulczyńska-Przybik Maciej Dulewicz Renata Borawska Monika Zajkowska Agnieszka Słowik Barbara Mroczko Potential Utility of Cerebrospinal Fluid Glycoprotein Nonmetastatic Melanoma Protein B as a Neuroinflammatory Diagnostic Biomarker in Mild Cognitive Impairment and Alzheimer’s Disease Journal of Clinical Medicine Alzheimer’s disease GPNMB YKL-40 neuroinflammation |
| title | Potential Utility of Cerebrospinal Fluid Glycoprotein Nonmetastatic Melanoma Protein B as a Neuroinflammatory Diagnostic Biomarker in Mild Cognitive Impairment and Alzheimer’s Disease |
| title_full | Potential Utility of Cerebrospinal Fluid Glycoprotein Nonmetastatic Melanoma Protein B as a Neuroinflammatory Diagnostic Biomarker in Mild Cognitive Impairment and Alzheimer’s Disease |
| title_fullStr | Potential Utility of Cerebrospinal Fluid Glycoprotein Nonmetastatic Melanoma Protein B as a Neuroinflammatory Diagnostic Biomarker in Mild Cognitive Impairment and Alzheimer’s Disease |
| title_full_unstemmed | Potential Utility of Cerebrospinal Fluid Glycoprotein Nonmetastatic Melanoma Protein B as a Neuroinflammatory Diagnostic Biomarker in Mild Cognitive Impairment and Alzheimer’s Disease |
| title_short | Potential Utility of Cerebrospinal Fluid Glycoprotein Nonmetastatic Melanoma Protein B as a Neuroinflammatory Diagnostic Biomarker in Mild Cognitive Impairment and Alzheimer’s Disease |
| title_sort | potential utility of cerebrospinal fluid glycoprotein nonmetastatic melanoma protein b as a neuroinflammatory diagnostic biomarker in mild cognitive impairment and alzheimer s disease |
| topic | Alzheimer’s disease GPNMB YKL-40 neuroinflammation |
| url | https://www.mdpi.com/2077-0383/12/14/4689 |
| work_keys_str_mv | AT juliadoroszkiewicz potentialutilityofcerebrospinalfluidglycoproteinnonmetastaticmelanomaproteinbasaneuroinflammatorydiagnosticbiomarkerinmildcognitiveimpairmentandalzheimersdisease AT agnieszkakulczynskaprzybik potentialutilityofcerebrospinalfluidglycoproteinnonmetastaticmelanomaproteinbasaneuroinflammatorydiagnosticbiomarkerinmildcognitiveimpairmentandalzheimersdisease AT maciejdulewicz potentialutilityofcerebrospinalfluidglycoproteinnonmetastaticmelanomaproteinbasaneuroinflammatorydiagnosticbiomarkerinmildcognitiveimpairmentandalzheimersdisease AT renataborawska potentialutilityofcerebrospinalfluidglycoproteinnonmetastaticmelanomaproteinbasaneuroinflammatorydiagnosticbiomarkerinmildcognitiveimpairmentandalzheimersdisease AT monikazajkowska potentialutilityofcerebrospinalfluidglycoproteinnonmetastaticmelanomaproteinbasaneuroinflammatorydiagnosticbiomarkerinmildcognitiveimpairmentandalzheimersdisease AT agnieszkasłowik potentialutilityofcerebrospinalfluidglycoproteinnonmetastaticmelanomaproteinbasaneuroinflammatorydiagnosticbiomarkerinmildcognitiveimpairmentandalzheimersdisease AT barbaramroczko potentialutilityofcerebrospinalfluidglycoproteinnonmetastaticmelanomaproteinbasaneuroinflammatorydiagnosticbiomarkerinmildcognitiveimpairmentandalzheimersdisease |